Deutsche Bank Aktiengesellschaft reaffirmed their buy rating on shares of GSK (LON:GSK – Free Report) in a research report report published on Friday, MarketBeat reports. They currently have a GBX 1,950 ($24.66) price objective on the stock.
Several other research analysts have also recently weighed in on GSK. JPMorgan Chase & Co. reiterated an underweight rating on shares of GSK in a research note on Tuesday, June 18th. Citigroup reiterated a buy rating and set a GBX 2,100 ($26.56) price target on shares of GSK in a research note on Monday, June 24th. Shore Capital reiterated a buy rating on shares of GSK in a research note on Thursday, June 27th. Barclays reiterated an equal weight rating and set a GBX 1,725 ($21.82) price target on shares of GSK in a research note on Tuesday, May 7th. Finally, Jefferies Financial Group reiterated a buy rating and set a GBX 2,100 ($26.56) price target on shares of GSK in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of Moderate Buy and a consensus target price of GBX 1,791.25 ($22.66).
Get Our Latest Analysis on GSK
GSK Trading Down 0.2 %
GSK Cuts Dividend
The company also recently announced a dividend, which will be paid on Thursday, July 11th. Investors of record on Thursday, May 16th will be paid a dividend of GBX 15 ($0.19) per share. This represents a dividend yield of 0.9%. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio (DPR) is 5,504.59%.
Insider Activity at GSK
In related news, insider Wendy Becker purchased 446 shares of GSK stock in a transaction on Thursday, June 20th. The shares were bought at an average cost of GBX 1,614 ($20.41) per share, for a total transaction of £7,198.44 ($9,105.03). 1.60% of the stock is owned by corporate insiders.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
- Five stocks we like better than GSK
- How to Start Investing in Real Estate
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What Makes a Stock a Good Dividend Stock?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Energy and Oil Stocks Explained
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.